I-FDA-Iyavunyelwa nge-Spondyloarthropathies ethize ne-Plaque Psoriasis
I-Cosentyx (secukinumab), eyakhiwe yi-Novartis, yamukelwa yi-FDA ngoJanuwari 15, 2016 yokwelapha abantu abadala abane- spyyllicis ankylosing esebenzayo kanye ne- acthritis esebenzayo ye- psoriatic . Kwakuvele kuvunyelwe ngoJanuwari 2015 ukuba i- psoriasis enomthamo oyindilinga kubantu abadala abafuna ukwelashwa okuhlelekile noma i-phototherapy. I-ankylosing spondylitis ne-psoriatic arthritis yizinhlobo zokuvuvukala kwe-arthritis ezihlukaniswa njenge- spondyloarthropathies .
Ukwamukelwa kwe-Cosentyx ye-ankylosing spondylitis ne-psoriatic arthritis kwakusekelwe emiphumeleni emibili ye-spondylitis e-ankylosing ne-psoriatic arthritis ye-phasebo-elawulwa yi-Phase III yokuhlolwa kwemithi ehlola ukuphepha nokusebenza. Izilingo zazibandakanya abantu abadala abangaphezu kuka-1 500 ababenesinye sezimo ezimbili.
Kuyini i-Cosentyx?
I-Cosentyx iyimithi esebenza ohlelweni lwezivikela- mzimba ukuphatha izifo nezimo ezibalwe ngenhla. Ngokuqondile, i-Cosentyx iyinhlangano ye-interleukin-17A (i-IL-17A) yomuntu-i -anti-monoclonal antibody ehlangene ne-IL-17A futhi ivimba ukusebenzisana ne-receptor IL-17. Ngumphikisi wokuqala we-interleukin-17A avunyelwe ukwelapha i-spondylitis e-ankylosing, i-psoriatic arthritis, ne-psoriasis yama-plaque.
Ukuphathwa Kwezidakamizwa Kuyini?
I-Cosentyx ilawulwa yi-injection subcutaneous emathangeni angaphezulu noma esiswini. I-Cosentyx iyatholakala njengesisombululo (150 mg / mL) ku-Sensoready ipeni eyodwa.
Iphinde itholakale kusetshenziseni olulodwa olusetshenziswayo (150 mg / mL). Kukhona i-vial okufanele ibuyiswe kabusha, futhi, kodwa yilabo abaqeqeshiwe bezempilo kuphela.
Kubantu abane-arthritis esebenzayo ye-psoriatic noma i-ankylosing spondylitis, umthamo ophakanyisiwe we-Cosentyx uhilela umthamo wokulayisha we-150 mg emasontweni 0, 1, 2, 3 no-4, okulandelwa njalo ngamasonto amane.
Kungabuye kunikezwe njalo ngemva kwamasonto amane ngaphandle komthamo wokulayisha. Uma lesi sifo sihlala sikhuthele, umthamo we 300 mg ungacatshangelwa. I-psoriasis ye-plaque, umthamo onconywayo ungama 300 mg emasontweni 0, 1, 2, 3, 4 kanye nawo onke amasonto amane emva kwalokho. Umthamo ophansi we-150 mg ungakwanela kwabanye abantu. Kwabantu abane-arthritis ye-psoriatic kanye ne-psoriasis ye-plaque, i-protocol ye-plaque psoriasis inconywa.
Ubani Okungafanele Asebenzise i-Cosentyx?
Abantu abaye babhekana nesifo esibi kakhulu ku-secukinumab akufanele basebenzise imithi.
Imiphumela Ejwayelekile Ejwayelekile
Imiphumela emibi kakhulu ehlobene neCosentyx ihlanganisa i-nasopharyngitis (izimpawu ezibandayo), izifo ezingaphezulu zokuphefumula, nokuhuda. Eminye imiphumela emibi ingenzeka futhi uma uhlangabezana nakho konke okukhathazayo, xhumana nodokotela wakho.
Ukuxwayiswa nokuqapha
Ezinye izixwayiso nezixwayiso zihlobene ne-Cosentyx:
- Izifo ezinzima zenzeke ngokusetshenziswa kwayo. Ngenxa yokuthi i-Cosentyx yenza isistimu yomzimba, inganciphisa ikhono lakho lokulwa nezifo futhi ingangandisa ingozi yezifo. Uma ukutheleleka okungathí sina kuqhubeka ngenkathi usebenzisa i-Cosentyx, yeka imithi ngenkathi ukutheleleka kukwelashwa. Eqinisweni, abantu abanesifo samanje, ukutheleleka okungapheli, noma umlando wezifo ezithathelwanayo kufanele baqaphele futhi baxoxe ngomlando wabo wokutheleleka nodokotela wabo ngaphambi kokusebenzisa i-Cosentyx.
- Ngaphambi kokuqala ukwelashwa ne-Cosentyx, kufanele uhlolwe isifo sofuba . Uma udokotela wakho ezwa ukuthi usengozini yesifo sofuba ngenxa yokuthi uvezwe, ungaphathwa nge-TB ngaphambi kokuqala i-Cosentyx kanti ngenkathi uphathwa nge-Cosentyx.
- Ezilingo zomtholampilo, izimo ezintsha zokuqala zezifo zesifo sofuba zaphawulwa, kanye nokukhushulwa kulabo abane-IBD. Ukuqapha kufanele kusetshenziswe lapho i-Cosentyx inqunywe kumuntu owaziwa yi-IBD.
- I-Anaphylactic noma i-alteric reaction effect ingenzeka. Uma kwenzeka, i-Cosentyx kufanele isuswe masinyane futhi kufanele ufune usizo lwezokwelapha.
- Imishanguzo ephilayo akufanele inikezwe kuwe, uma usebenzisa i-Cosentyx.
- Kubekho izifundo ezifanele ze-Cosentyx kwabesifazane abakhulelwe. Ayaziwa ukuthi i-Cosentyx ixoshiwe ebisi lomuntu noma isetshenziswe ngendlela efanele ngemuva kokungenwa. Ukuqapha kufanele kusetshenziswe.
Izwi elivela
Njengoba siyazi, izidakamizwa azifani ngendlela efana nabo bonke abantu abazama. Yingakho kubalulekile ukuba nezinketho eziningana zokwelapha. Njengoba i-Cosentyx iyisidakamizwa sokuqala ukukhomba i-interleukin-17A, indlela yonyango iyatholakala manje engatholakali ngaphambi kokuba kuvunywe izidakamizwa.
Ukuze usebenzise i-Cosentyx ngokuphepha, kufanele ufunde ukujova ngendlela efanele, uqaphele imiphumela emibi kanye nezixwayiso, futhi ubike izenzakalo ezimbi uma kwenzeka. Uma unesithakazelo ekufundeni kabanzi ngalolu khetho, ulethe kuchwepheshe wakho wezempilo. Uzohamba nawe afike esinqumweni esihle kunazo zonke.
Imithombo:
I-Cosentyx. Ukubeka imininingwane . I-Novartis Pharmaceuticals Corporation. I-Januwari ebuyekeziwe e-2016.
I-Cosentyx. Umhlahlandlela Wezokwelapha . I-Novartis Pharmaceuticals Corporation. I-Januwari ebuyekeziwe e-2016.